Treatment

Maridebart Cafraglutide clinical trials

Active studies that list Maridebart Cafraglutide as an intervention or treatment.

6active studies

3recruiting now

8countries represented

783largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia783 locations

AmgenSponsor

Updated 2026-09-03 · NCT07037433See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Active, not recruitingPhase 1

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Overweight, ObesityCondition

COC, Maridebart CafraglutideTreatment

United States2 locations

AmgenSponsor

Updated 2026-07-20 · NCT07523711See eligibility →

Active, not recruitingPhase 1

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Overweight, ObesityCondition

Maridebart Cafraglutide, MoxifloxacinTreatment

United States2 locations

AmgenSponsor

Updated 2026-01-23 · NCT07229157See eligibility →

Active, not recruitingPhase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ObesityCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia243 locations

AmgenSponsor

Updated 2025-10-20 · NCT06858839See eligibility →

Related treatments

Placebo421 Tirzepatide119 Semaglutide91 Control30 Exercise27 Orforglipron21

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.